Multi-Omics Data Integration Analysis of an Immune-Related Gene Signature in LGG Patients With Epilepsy

Background The tumor immune microenvironment significantly affects tumor occurrence, progression, and prognosis, but its impact on the prognosis of low-grade glioma (LGG) patients with epilepsy has not been reported. Hence, the purpose of this study is to explore its effect on LGG patients with epilepsy. Methods The data of LGG patients derived from the TCGA database. The level of immune cell infiltration and the proportion of 22 immune cells were evaluated by ESTIMATE and CIBERSORT algorithms, respectively. The Cox and LASSO regression analysis was adopted to determine the DEGs, and further established the clustering and risk score models. The association between genomic alterations and risk score was investigated using CNV and somatic mutation data. GSVA was adopted to identify the immunological pathways, immune infiltration and inflammatory profiles related to the signature genes. The Tumor Immune Dysfunction and Exclusion (TIDE) algorithm and GDSC database were used to predict the patient’s response to immunotherapy and chemotherapy, respectively. Results The prognosis of LGG patients with epilepsy was associated with the immune score. Three prognostic DEGs (ABCC3, PDPN, and INA) were screened out. The expression of signature genes was regulated by DNA methylation. The clustering and risk score models could stratify glioma patients into distinct prognosis groups. The risk score was an independent predictor in prognosis, with a high risk-score indicating a poor prognosis, more malignant clinicopathological and genomic aberration features. The nomogram had the better predictive ability. Patients at high risk had a higher level of macrophage infiltration and increased inflammatory activities associated with T cells and macrophages. While the higher percentage of NK CD56bright cell and more active inflammatory activity associated with B cell were present in the low-risk patients. The signature genes participated in the regulation of immune-related pathways, such as IL6-JAK-STAT3 signaling, IFN-α response, IFN-γ response, and TNFA-signaling-via-NFKB pathways. The high-risk patients were more likely to benefit from anti-PD1 and temozolomide (TMZ) treatment. Conclusion An immune-related gene signature was established based on ABCC3, PDPN, and INA, which can be used to predict the prognosis, immune infiltration status, immunotherapy and chemotherapy response of LGG patients with epilepsy.

[1]  K. Rajmohan,et al.  Alpha Internexin: A Surrogate Marker for 1p/19q Codeletion and Prognostic Marker in Anaplastic (WHO grade III) Gliomas , 2020, Neurology India.

[2]  T. Yahata,et al.  Podoplanin is indispensable for cell motility and platelet-induced epithelial-to-mesenchymal transition-related gene expression in esophagus squamous carcinoma TE11A cells , 2020, Cancer Cell International.

[3]  A. Xu,et al.  Pan-Cancer Analysis of Radiotherapy Benefits and Immune Infiltration in Multiple Human Cancers , 2020, Cancers.

[4]  Chen Zhu,et al.  IFI30 Is a Novel Immune-Related Target with Predicting Value of Prognosis and Treatment Response in Glioblastoma , 2020, OncoTargets and therapy.

[5]  Y. Lv,et al.  Suspension State Promotes Drug Resistance of Breast Tumor Cells by Inducing ABCC3 Overexpression , 2019, Applied Biochemistry and Biotechnology.

[6]  David T. W. Jones,et al.  The Power of Human Cancer Genetics as Revealed by Low-Grade Gliomas. , 2019, Annual review of genetics.

[7]  Guang-zhi Zhu,et al.  Prognostic significance and molecular mechanisms of adenosine triphosphate-binding cassette subfamily C members in gastric cancer , 2019, Medicine.

[8]  J. Roliński,et al.  PD-L1/PD-1 Axis in Glioblastoma Multiforme , 2019, International journal of molecular sciences.

[9]  Bo Liu,et al.  A prognostic signature of five pseudogenes for predicting lower-grade gliomas. , 2019, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[10]  G. Piazza,et al.  Pharmacological inhibition of ABCC3 slows tumour progression in animal models of pancreatic cancer , 2019, Journal of Experimental & Clinical Cancer Research.

[11]  Z. Liu,et al.  Oligodendroglial tumours: subventricular zone involvement and seizure history are associated with CIC mutation status , 2019, BMC Neurology.

[12]  S. Raza,et al.  Comparative proteogenomic characterization of glioblastoma , 2019, CNS oncology.

[13]  M. Quintanilla,et al.  Podoplanin in Inflammation and Cancer , 2019, International journal of molecular sciences.

[14]  Helen Y Wang,et al.  Cancer Stem Cells and Immunosuppressive Microenvironment in Glioma , 2018, Front. Immunol..

[15]  Yassen Assenov,et al.  Maftools: efficient and comprehensive analysis of somatic variants in cancer , 2018, Genome research.

[16]  Y. Chu,et al.  The IFN-γ/PD-L1 axis between T cells and tumor microenvironment: hints for glioma anti-PD-1/PD-L1 therapy , 2018, Journal of Neuroinflammation.

[17]  Yingying Zhang,et al.  TGF-β1 secreted by M2 phenotype macrophages enhances the stemness and migration of glioma cells via the SMAD2/3 signalling pathway , 2018, International journal of molecular medicine.

[18]  X. Liu,et al.  Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response , 2018, Nature Medicine.

[19]  A. Feyissa,et al.  Brain tumor related-epilepsy. , 2018, Neurologia i neurochirurgia polska.

[20]  Minhu Chen,et al.  Loss of expression and prognosis value of alpha-internexin in gastroenteropancreatic neuroendocrine neoplasm , 2018, BMC Cancer.

[21]  Dillon Y. Chen,et al.  Tumor-related epilepsy: epidemiology, pathogenesis and management , 2018, Journal of neuro-oncology.

[22]  G. Ishii,et al.  Podoplanin: An emerging cancer biomarker and therapeutic target , 2018, Cancer science.

[23]  Amy E. Morgan,et al.  The role of DNA methylation in ageing and cancer , 2018, Proceedings of the Nutrition Society.

[24]  J. Szustakowski,et al.  Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden , 2018, The New England journal of medicine.

[25]  D. Cahill,et al.  Isocitrate dehydrogenase‐mutant glioma: Evolving clinical and therapeutic implications , 2017, Cancer.

[26]  M. Weller,et al.  Autocrine activation of the IFN signaling pathway may promote immune escape in glioblastoma , 2017, Neuro-oncology.

[27]  T. Waldmann,et al.  IL15 Infusion of Cancer Patients Expands the Subpopulation of Cytotoxic CD56bright NK Cells and Increases NK-Cell Cytokine Release Capabilities , 2017, Cancer Immunology Research.

[28]  J. Huse,et al.  Mutational burden, immune checkpoint expression, and mismatch repair in glioma: implications for immune checkpoint immunotherapy , 2017, Neuro-oncology.

[29]  P. Geeleher.  pRRophetic R package , 2017 .

[30]  K. Srivenugopal,et al.  The Process and Regulatory Components of Inflammation in Brain Oncogenesis , 2017, Biomolecules.

[31]  B. Kamińska,et al.  Immune microenvironment of gliomas , 2017, Laboratory Investigation.

[32]  G. Multhoff,et al.  Immunological and Translational Aspects of NK Cell-Based Antitumor Immunotherapies , 2016, Front. Immunol..

[33]  N. Zhang,et al.  The EGFR pathway is involved in the regulation of PD-L1 expression via the IL-6/JAK/STAT3 signaling pathway in EGFR-mutated non-small cell lung cancer. , 2016, International journal of oncology.

[34]  J. Greenfield,et al.  Exploring the role of inflammation in the malignant transformation of low-grade gliomas , 2016, Journal of Neuroimmunology.

[35]  G. Huberfeld,et al.  Seizures and gliomas — towards a single therapeutic approach , 2016, Nature Reviews Neurology.

[36]  Helmut Kettenmann,et al.  The role of microglia and macrophages in glioma maintenance and progression , 2015, Nature Neuroscience.

[37]  J. Mesirov,et al.  The Molecular Signatures Database Hallmark Gene Set Collection , 2015 .

[38]  L. Panasci,et al.  Interferon-α/β enhances temozolomide activity against MGMT-positive glioma stem-like cells. , 2015, Oncology reports.

[39]  Alessandro Rosa,et al.  Enriched environment reduces glioma growth through immune and non-immune mechanisms in mice , 2015, Nature Communications.

[40]  W. Huber,et al.  Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2 , 2014, Genome Biology.

[41]  Paul Geeleher,et al.  pRRophetic: An R Package for Prediction of Clinical Chemotherapeutic Response from Tumor Gene Expression Levels , 2014, PloS one.

[42]  T. Macdonald,et al.  Th17-type cytokines, IL-6 and TNF-α synergistically activate STAT3 and NF-kB to promote colorectal cancer cell growth , 2014, Oncogene.

[43]  GogaliFoteini,et al.  CD3−CD16−CD56bright Immunoregulatory NK Cells are Increased in the Tumor Microenvironment and Inversely Correlate with Advanced Stages in Patients with Papillary Thyroid Cancer , 2013 .

[44]  G. Getz,et al.  Inferring tumour purity and stromal and immune cell admixture from expression data , 2013, Nature Communications.

[45]  Howard Colman,et al.  IDH1 and IDH2 Mutations in Gliomas , 2013, Current Neurology and Neuroscience Reports.

[46]  Justin Guinney,et al.  GSVA: gene set variation analysis for microarray and RNA-Seq data , 2013, BMC Bioinformatics.

[47]  S. Turley,et al.  Podoplanin: emerging functions in development, the immune system, and cancer , 2012, Front. Immun..

[48]  Michael Weller,et al.  Personalized care in neuro-oncology coming of age: why we need MGMT and 1p/19q testing for malignant glioma patients in clinical practice. , 2012, Neuro-oncology.

[49]  M. Maschio.  Brain Tumor-Related Epilepsy , 2012, Current neuropharmacology.

[50]  Drew M. Pardoll,et al.  The blockade of immune checkpoints in cancer immunotherapy , 2012, Nature Reviews Cancer.

[51]  Zhe-Sheng Chen,et al.  Multidrug resistance proteins (MRPs/ABCCs) in cancer chemotherapy and genetic diseases , 2011, The FEBS journal.

[52]  G. Getz,et al.  GISTIC2.0 facilitates sensitive and confident localization of the targets of focal somatic copy-number alteration in human cancers , 2011, Genome Biology.

[53]  K. Hoang-Xuan,et al.  Diagnostic and prognostic value of alpha internexin expression in a series of 409 gliomas. , 2011, European journal of cancer.

[54]  Matthew D. Wilkerson,et al.  ConsensusClusterPlus: a class discovery tool with confidence assessments and item tracking , 2010, Bioinform..

[55]  S. Gabriel,et al.  Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. , 2010, Cancer cell.

[56]  R. McLendon,et al.  Targeting Interleukin 6 Signaling Suppresses Glioma Stem Cell Survival and Tumor Growth , 2009, Stem cells.

[57]  S. Berntsson,et al.  Epileptic seizures and survival in early disease of grade 2 gliomas , 2009, European journal of neurology.

[58]  Achim Rody,et al.  T-cell metagene predicts a favorable prognosis in estrogen receptor-negative and HER2-positive breast cancers , 2009, Breast Cancer Research.

[59]  O. Clark,et al.  Papillary thyroid cancer , 2006, Current treatment options in oncology.

[60]  H. Urbach,et al.  An isomorphic subtype of long-term epilepsy-associated astrocytomas associated with benign prognosis , 2004, Acta Neuropathologica.

[61]  Ash A. Alizadeh,et al.  SUPPLEMENTARY NOTE , 1879, Botanical Gazette.

[62]  J. Mesirov,et al.  The Molecular Signatures Database (MSigDB) hallmark gene set collection. , 2015, Cell systems.

[63]  Daniel J Brat,et al.  Molecular genetics of gliomas. , 2014, Cancer journal.

[64]  G. Riggins,et al.  A survey of glioblastoma genomic amplifications and deletions , 2009, Journal of Neuro-Oncology.

[65]  R. Czepko,et al.  [Prognostic value of epileptic seizures in patients with cerebral gliomas]. , 2004, Annales Academiae Medicae Stetinensis.

[66]  K. Skullerud,et al.  Prevalence and prognostic significance of epilepsy in patients with gliomas. , 1998, European journal of cancer.

[67]  M. Glover.  The power to be human. , 1991, California hospitals.